Pharmacological inhibition of PARP1 was first introduced in cancer therapy to exploit synthetic lethality of BRCA1-deficient breast tumors (Fong et al., 2009) and is now widely tested in combination with DNA damaging chemotherapeutic drugs (Farmer et al., 2005). Here, PARP1 is linked to cancer.